Cargando…

Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD

Post-vaccination disease relapses have been reported in patients with MOGAD and AQP4-IgG+NMOSD. In this retrospective multicenter Italian study we assessed the frequency of relapses after SARS-CoV-2 vaccination. We included 56 cases: MOGAD, 30; AQP4-IgG+NMOSD, 26. Vaccines received were BNT162b2-Pfi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dinoto, Alessandro, Sechi, Elia, Ferrari, Sergio, Gajofatto, Alberto, Orlandi, Riccardo, Solla, Paolo, Maccabeo, Alessandra, Maniscalco, Giorgia Teresa, Andreone, Vincenzo, Sartori, Arianna, Manganotti, Paolo, Rasia, Sarah, Capra, Ruggero, Mancinelli, Chiara Rosa, Mariotto, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607690/ https://www.ncbi.nlm.nih.gov/pubmed/35216793 http://dx.doi.org/10.1016/j.msard.2021.103424

Ejemplares similares

Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD
por: Fadda, Giulia, et al.
Publicado: (2022)

The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD
por: Berhanu, David, et al.
Publicado: (2023)

Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort
por: Dauby, Solène, et al.
Publicado: (2021)

AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?
por: Fragoso, Diego Cardoso, et al.
Publicado: (2023)

The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis
por: Roca-Fernández, A, et al.
Publicado: (2021)

Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD
por: Schroeder-Castagno, Maria, et al.
Publicado: (2022)

NMOSD and MOGAD Dual Positivity: An Extremely Rare Phenomenon
por: Agarwal, Ayush, et al.
Publicado: (2022)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management
por: Sechi, Elia, et al.
Publicado: (2022)

Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2
por: Graf, Jonas, et al.
Publicado: (2020)

Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1
por: Graf, Jonas, et al.
Publicado: (2020)

Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD
por: Derdelinckx, Judith, et al.
Publicado: (2021)

Demystifying MOGAD and Double Seronegative NMOSD Further With IL-6 Blockade
por: Yong, Kok Pin, et al.
Publicado: (2021)

Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status
por: S, Mariotto, et al.
Publicado: (2017)

Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD
por: Kim, Sohyeon, et al.
Publicado: (2023)

COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD
por: Yeo, Tianrong, et al.
Publicado: (2022)

Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD)
por: Gernert, Jonathan A., et al.
Publicado: (2022)

Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease
por: Dinoto, Alessandro, et al.
Publicado: (2022)

Helicobacter pylori infection may influence prevalence and disease course in myelin oligodendrocyte glycoprotein antibody associated disorder (MOGAD) similar to MS but not AQP4-IgG associated NMOSD
por: Malli, Chaithra, et al.
Publicado: (2023)

The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
por: Sen, Sedat, et al.
Publicado: (2022)

Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD
por: Lin, Liuyu, et al.
Publicado: (2022)

Comment on “Anti-NMDA receptor encephalitis presenting as new onset refractory status epilepticus in COVID-19”
por: Dinoto, Alessandro, et al.
Publicado: (2020)

The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON
por: Yao, Yajun, et al.
Publicado: (2022)

Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies
por: Asseyer, Susanna, et al.
Publicado: (2020)

AQP4‐IgG positive paraneoplastic NMOSD: A case report and review
por: Ding, Manqiu, et al.
Publicado: (2021)

Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) und Anti-Myelin-Oligodendrozyten-Glykoprotein-Antikörper-assoziierte Erkrankungen (MOGAD)
por: Seifert-Held, Thomas
Publicado: (2022)

Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder
por: Arru, Giannina, et al.
Publicado: (2017)

Microstructural visual system changes in AQP4-antibody–seropositive NMOSD
por: Oertel, Frederike C., et al.
Publicado: (2017)

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD
por: Shosha, Eslam, et al.
Publicado: (2018)

COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore
por: Yeo, Tianrong, et al.
Publicado: (2023)

Paraneoplastic NMOSD associated with EG junction adenocarcinoma expressing unprotected AQP4
por: Sudo, Atsushi, et al.
Publicado: (2018)

Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD
por: Jitprapaikulsan, Jiraporn, et al.
Publicado: (2020)

A case report on recurrent area postrema syndrome in AQP4-IgG-positive NMOSD
por: Shrestha, Ramesh, et al.
Publicado: (2022)

Different clinical phenotypes of AQP4-IgG positive NMOSD in two first degree relatives
por: Ssemmanda, Salvatore, et al.
Publicado: (2023)

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
por: Paul, Friedemann, et al.
Publicado: (2023)

Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: Data from a nationwide registry in Argentina
por: Contentti, Edgar Carnero, et al.
Publicado: (2021)

Telemedicine for routinary multiple sclerosis follow-up during SARS-CoV2 pandemic: A single center experience
por: Sartori, Arianna, et al.
Publicado: (2021)

Sars-CoV2 pandemic and lockdown reported consequences on people with multiple sclerosis
por: Sartori, Arianna, et al.
Publicado: (2021)

An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD
por: Carnero Contentti, Edgar, et al.
Publicado: (2021)

Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD
por: Finke, Carsten, et al.
Publicado: (2016)

AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD
por: Prain, Kerri, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g3rrj43nh56s7eutobvcvtr59b